Literature DB >> 33880079

Magnetic Resonance Imaging of Spinal Cord Lesions in Patients with Multiple Sclerosis in Saskatchewan, Canada.

Aman Saini, Kevin Bach, Ilia Poliakov, Katherine B Knox, Michael C Levin.   

Abstract

BACKGROUND: Spinal cord lesions (SCLs) contribute to disability in multiple sclerosis (MS). Data in Saskatchewan, Canada, concerning SCLs and their association with disability levels in patients with MS are lacking. The study objectives were to identify clinicodemographic profiles of patients with MS with respect to spinal cord magnetic resonance imaging (MRI) involvement; determine the frequency of individuals with MRI SCLs; and explore differences between patients with MS with and without SCLs with respect to disability and disease-modifying therapy status.
METHODS: A monocentric, cross-sectional, retrospective review of prospectively collected data from 532 research-consented patients seen at Saskatoon MS Clinic was performed. Data were collected from a database and electronic medical records.
RESULTS: Of the 356 patients (66.9%) with an SCL, 180 (50.6%) had only cervical cord lesions. Median Expanded Disability Status Scale (EDSS), ambulation, and pyramidal scores of patients with SCLs were higher than those of patients without SCLs. Of patients with EDSS scores of at least 6, those with SCLs were younger than those without SCLs (P = .01). Patients with SCLs were 55% less likely to have been on continuous disease-modifying therapy since diagnosis than patients without SCLs (adjusted odds ratio, 0.45; 95% CI, 0.25-0.81; P = .008).
CONCLUSIONS: Prevalence and association with disability of SCLs in patients with MS are comparable with existing literature. Patients with MS with SCLs have higher levels of disability and attain EDSS scores of at least 6 at a younger age.
© 2021 Consortium of Multiple Sclerosis Centers.

Entities:  

Keywords:  Disease-modifying therapy (DMT); Magnetic resonance imaging (MRI); Multiple sclerosis (MS); Spinal cord lesions

Year:  2020        PMID: 33880079      PMCID: PMC8047683          DOI: 10.7224/1537-2073.2019-081

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  24 in total

1.  Smoking is a risk factor for multiple sclerosis: a metanalysis.

Authors:  C H Hawkes
Journal:  Mult Scler       Date:  2007-02-16       Impact factor: 6.312

2.  Spinal cord pathology in multiple sclerosis.

Authors:  Hans Lassmann
Journal:  Lancet Neurol       Date:  2015-03-04       Impact factor: 44.182

3.  New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom.

Authors:  Alan Thompson; Gisela Kobelt; Jenny Berg; Daniela Capsa; Jennifer Eriksson; David Miller
Journal:  Mult Scler       Date:  2017-08       Impact factor: 6.312

Review 4.  Multiple Sclerosis.

Authors:  Daniel S Reich; Claudia F Lucchinetti; Peter A Calabresi
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

5.  Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Authors:  Alexander Rae-Grant; Gregory S Day; Ruth Ann Marrie; Alejandro Rabinstein; Bruce A C Cree; Gary S Gronseth; Michael Haboubi; June Halper; Jonathan P Hosey; David E Jones; Robert Lisak; Daniel Pelletier; Sonja Potrebic; Cynthia Sitcov; Rick Sommers; Julie Stachowiak; Thomas S D Getchius; Shannon A Merillat; Tamara Pringsheim
Journal:  Neurology       Date:  2018-04-24       Impact factor: 9.910

6.  Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study.

Authors:  J M Stankiewicz; M Neema; D C Alsop; B C Healy; A Arora; G J Buckle; T Chitnis; C R G Guttmann; D Hackney; R Bakshi
Journal:  J Neurol Sci       Date:  2009-04-15       Impact factor: 3.181

Review 7.  Post-translational modifications of proteins: implications for aging, antigen recognition, and autoimmunity.

Authors:  Paul A C Cloos; Stephan Christgau
Journal:  Biogerontology       Date:  2004       Impact factor: 4.277

Review 8.  Cigarette smoking and inflammation revisited.

Authors:  Oren Rom; Katia Avezov; Dror Aizenbud; Abraham Z Reznick
Journal:  Respir Physiol Neurobiol       Date:  2013-01-29       Impact factor: 1.931

9.  Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells.

Authors:  D Makrygiannakis; M Hermansson; A-K Ulfgren; A P Nicholas; A J W Zendman; A Eklund; J Grunewald; C M Skold; L Klareskog; A I Catrina
Journal:  Ann Rheum Dis       Date:  2008-04-15       Impact factor: 19.103

10.  Treatment Patterns, Healthcare Resource Utilization, and Costs Among Medicare Patients with Multiple Sclerosis in Relation to Disease-Modifying Therapy and Corticosteroid Treatment.

Authors:  Marie Sanchirico; Amanda Caldwell-Tarr; Pallavi Mudumby; Lobat Hashemi; Robert Dufour
Journal:  Neurol Ther       Date:  2018-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.